NeurAxis Announces Over $8M In IB-Stim Revenue
Portfolio Pulse from Happy Mohamed
NeurAxis, Inc. (NYSE American: NRXS) announced it has generated over $8 million in revenue from its proprietary IB-Stim™ technology. The sales began after the company received FDA clearance for the technology in the pediatric treatment of functional abdominal pain and irritable bowel syndrome. The company is also conducting clinical trials for four additional pediatric indications.
August 17, 2023 | 1:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NeurAxis' revenue generation from its proprietary IB-Stim™ technology could positively impact its stock. The ongoing clinical trials for additional indications could further boost its market position.
The reported revenue indicates a successful commercial launch of the IB-Stim™ technology. The ongoing clinical trials for additional indications suggest potential for further market expansion and revenue growth, which could positively impact the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100